Fatty Acid Side-Chain Polypeptides for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Polypeptide-based drugs face challenges with poor oral efficacy, low bioavailability, and unpredictable delivery effects due to limitations in absorption in the human body, necessitating injection-based administration and causing patient inconvenience.
Innovation Solution
Modification of polypeptide molecules with a fatty acid-containing side chain in the form of Z1+Z2+Z3, where Z1 is a C16-C22 fatty diacid, Z2 is selected from specific amino acids, and Z3 is AEEA(s), to enhance activity, selectivity, and bioavailability for oral delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If polypeptide-based drugs are administered orally, then patient convenience is improved, but oral bioavailability remains low due to absorption limitations
Solution Approach 1:
The patent applies composite materials by combining the polypeptide drug molecule with a fatty acid-containing side chain (comprising Z1: C16-C22 fatty diacid, Z2: specific amino acid, and Z3: AEEA units) to create a hybrid structure. This composite polypeptide derivative maintains the biological activity of the original drug while gaining improved membrane permeability and oral absorption characteristics from the fatty acid component, thereby resolving the contradiction between oral administration convenience and low bioavailability.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of the polypeptide through addition of the fatty acid-containing side chain. This structural modification alters key parameters including lipophilicity, molecular weight, and amphipathic character, which collectively enhance the drug's ability to cross biological membranes and achieve sufficient oral bioavailability while maintaining therapeutic efficacy.
2Reliability
If polypeptide molecules are modified with fatty acid-containing side chains, then oral bioavailability is improved, but molecular structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the fatty acid-containing side chain into distinct functional modules: Z1 (fatty diacid portion providing lipophilicity), Z2 (amino acid portion providing structural stability), and Z3 (AEEA repeating units providing amphipathic character). This modular segmentation allows systematic optimization of each component's contribution to oral bioavailability while managing overall molecular complexity through standardized building blocks.
3Manufacturing precision
If polypeptide derivatives are designed with specific side chain structures, then activity selectivity is improved, but synthesis complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying specific parameters of the side chain structure: the carbon chain length of the fatty diacid (C16-C22), the identity of the amino acid (Z2), and the number of AEEA repeating units (Z3). These controlled parameter variations enable precise tuning of activity selectivity for different polypeptide targets while maintaining a standardized synthetic approach that manages complexity through repeatable modification protocols.
Data Source
Figure 1~3
Figure 4~6
AI summary
Provided herein are use of a fatty acid-containing side chain in improving activity, activity selectivity, and oral availability of a polypeptide derivative, a method for achieving the use, and a polypeptide derivative modified by the side chain.